GemcitabineRecent, repeatedEvidence- NCT07869836 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)” · registered Oct 2026
- NCT07829783 · Merck & Co., Inc · Phase 3 · live · background · “Gemcitabine” · registered Sep 2026
- NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2026
- NCT07129993 · Daiichi Sankyo · Phase 3 · live · comparator · “Gemcitabine” · registered Aug 2025
- NCT07106762 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Gemcitabine” · registered Aug 2025
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 88 studies | 913 studies | background 14 · comparator 9 · standard-care 1 |
CisplatinRecent, repeatedEvidence- NCT07829783 · Merck & Co., Inc · Phase 3 · live · background · “Cisplatin” · registered Sep 2026
- NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Cisplatin” · registered Apr 2026
- NCT07129993 · Daiichi Sankyo · Phase 3 · live · background · “Cisplatin” · registered Aug 2025
- NCT07106762 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Cisplatin” · registered Aug 2025
- NCT06960577 · AstraZeneca · Phase 2 · live · background · “Cisplatin” · registered Apr 2025
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 77 studies | 812 studies | background 16 · comparator 6 |
NivolumabRecent, repeatedEvidence- NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Nivolumab” · registered Jun 2026
- NCT06879145 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Nivolumab Injection” · registered Mar 2025
- NCT06059547 · CatalYm GmbH · Phase 2 · background · “Nivolumab” · registered Aug 2023
- NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Nivolumab” · registered Feb 2022
- NCT04180371 · BicycleTx Limited · Phase 2 · live · background · “Nivolumab” · registered Nov 2019
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 44 studies | 44 studies | comparator 2 · background 4 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07129993 · Daiichi Sankyo · Phase 3 · live · background · “Carboplatin” · registered Aug 2025
- NCT07106762 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Carboplatin” · registered Aug 2025
- NCT05911295 · Pfizer · Phase 3 · live · comparator · “carboplatin” · registered Jun 2023
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Carboplatin” · registered Aug 2021
- NCT04887831 · Pharmacosmos A/S · Phase 2 · background · “Carboplatin” · registered May 2021
| Eli Lilly and Company16% of its industry studies | 33 studies | 45 studies | background 8 · comparator 2 |
pembrolizumabRecent, repeatedEvidence- NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Pembrolizumab” · registered Jun 2026
- NCT07218380 · Eli Lilly and Company · Phase 3 · live · background · “Pembrolizumab” · registered Oct 2025
- NCT06225596 · BicycleTx Limited · Phase 2 · live · background · “Pembrolizumab” · registered Jan 2024
- NCT04561362 · BicycleTx Limited · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2020
- NCT03311334 · Sumitomo Pharma Co., Ltd. · Phase 2 · background · “Pembrolizumab” · registered Oct 2017
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 33 studies | 34 studies | background 5 · comparator 1 |
avelumabRecent, repeatedEvidence- NCT06424717 · Merck KGaA, Darmstadt, Germany · Phase 2 · background · “Avelumab” · registered May 2024
- NCT06225596 · BicycleTx Limited · Phase 2 · live · comparator · “Avelumab” · registered Jan 2024
- NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Avelumab” · registered Feb 2022
- NCT04887831 · Pharmacosmos A/S · Phase 2 · background · “Avelumab” · registered May 2021
| Pfizer44% of its industry studiesUS: Merck KGaA, Darmstadt, Germany (FDA 2017)EU: Merck KGaA, Darmstadt, Germany (EMA 2017) | 33 studies | 22 studies | comparator 1 · background 3 |
DocetaxelRecent, repeatedEvidence- NCT07419295 · Merck & Co., Inc · Phase 3 · live · comparator · “Docetaxel” · registered Feb 2026
- NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Docetaxel” · registered Aug 2021
- NCT03474107 · Astellas Pharma Inc · Phase 3 · comparator · “Docetaxel” · registered Mar 2018
- NCT02426125 · Eli Lilly and Company · Phase 3 · background · “Docetaxel” · registered Apr 2015
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 22 studies | 22 studies | comparator 4 · background 3 |
MitomycinRecent, repeatedEvidence- NCT07829783 · Merck & Co., Inc · Phase 3 · live · background · “MMC” · registered Sep 2026
- NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Mitomycin C” · registered Apr 2026
- NCT04241185 · Merck & Co., Inc · Phase 3 · live · background · “Mitomycin C (MMC)” · registered Jan 2020
- NCT04172675 · Johnson & Johnson · Phase 2 · standard-care · “Investigator Choice (Mitomycin C)” · registered Nov 2019
- NCT01200992 · Bioniche Life Sciences Inc. · Phase 3 · comparator · “Mitomycin C” · registered Sep 2010
| UroGen Pharma Ltd.70% of its industry studies | 22 studies | 23 studies | background 2 · comparator 2 · standard-care 1 |
FluorouracilRecent, repeatedEvidence- NCT07829783 · Merck & Co., Inc · Phase 3 · live · background · “5-FU” · registered Sep 2026
- NCT07566156 · Astellas Pharma Inc · Phase 3 · live · comparator · “Fluorouracil” · registered Apr 2026
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “5-Fluorouracil” · registered Aug 2021
- NCT04241185 · Merck & Co., Inc · Phase 3 · live · background · “Fluorouracil (5-FU)” · registered Jan 2020
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 22 studies | 23 studies | background 3 · comparator 1 |
enfortumab vedotinRecent, repeatedEvidence- NCT07720284 · AstraZeneca · Phase 3 · live · comparator · “Enfortumab vedotin” · registered Jun 2026
- NCT06305767 · Merck & Co., Inc · Phase 2 · live · background · “Enfortumab Vedotin” · registered Mar 2024
| Astellas Pharma Inc65% of its industry studiesUS: Astellas Pharma Inc (FDA 2019)EU: Astellas Pharma Inc (EMA 2022) | 22 studies | 22 studies | comparator 1 · background 1 |